Urigen Pharmaceuticals
305 East High Street
Suite 7
Bound Brook, NJ 08805
United States

ph: 732-369-5911

  • Home
  • About Us
  • Products in Development
  • Investor Relations
  • Contact Us
  • URG101
  • Learn About IC/BPS

      


 

 Presently, the only approved products for treating interstitial cystitis / bladder pain syndrome (IC/BPS) in the US and Europe, are based on clinical studies which have shown the drugs to be marginally effective. Consequently, there remains a significant need for new therapeutic interventions such as URG101 that can address the underlying disease process while also providing acute symptom relief.                        






 



Copyright 2020 Urigen . All rights reserved.

Terms of Use   *  Privacy Policy 

Urigen Pharmaceuticals
305 East High Street
Suite 7
Bound Brook, NJ 08805
United States

ph: 732-369-5911